Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

(2008) Arkadiusz Z. Dudek et al.   CANCER

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH

Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis

(2008) Christian Eichelberg et al.   EUROPEAN UROLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET